Adiso is a company headquartered in the United States.
Adiso develops novel therapies for inflammatory diseases using small molecules targeting neutrophil modulation and inflammasome inhibition, alongside single strain live biotherapeutic products with novel mechanisms of action.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.